1
|
Schmeisser S, Miccoli A, von Bergen M, Berggren E, Braeuning A, Busch W, Desaintes C, Gourmelon A, Grafström R, Harrill J, Hartung T, Herzler M, Kass GEN, Kleinstreuer N, Leist M, Luijten M, Marx-Stoelting P, Poetz O, van Ravenzwaay B, Roggeband R, Rogiers V, Roth A, Sanders P, Thomas RS, Marie Vinggaard A, Vinken M, van de Water B, Luch A, Tralau T. New approach methodologies in human regulatory toxicology - Not if, but how and when! Environ Int 2023; 178:108082. [PMID: 37422975 PMCID: PMC10858683 DOI: 10.1016/j.envint.2023.108082] [Citation(s) in RCA: 20] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/17/2023] [Revised: 06/30/2023] [Accepted: 07/01/2023] [Indexed: 07/11/2023]
Abstract
The predominantly animal-centric approach of chemical safety assessment has increasingly come under pressure. Society is questioning overall performance, sustainability, continued relevance for human health risk assessment and ethics of this system, demanding a change of paradigm. At the same time, the scientific toolbox used for risk assessment is continuously enriched by the development of "New Approach Methodologies" (NAMs). While this term does not define the age or the state of readiness of the innovation, it covers a wide range of methods, including quantitative structure-activity relationship (QSAR) predictions, high-throughput screening (HTS) bioassays, omics applications, cell cultures, organoids, microphysiological systems (MPS), machine learning models and artificial intelligence (AI). In addition to promising faster and more efficient toxicity testing, NAMs have the potential to fundamentally transform today's regulatory work by allowing more human-relevant decision-making in terms of both hazard and exposure assessment. Yet, several obstacles hamper a broader application of NAMs in current regulatory risk assessment. Constraints in addressing repeated-dose toxicity, with particular reference to the chronic toxicity, and hesitance from relevant stakeholders, are major challenges for the implementation of NAMs in a broader context. Moreover, issues regarding predictivity, reproducibility and quantification need to be addressed and regulatory and legislative frameworks need to be adapted to NAMs. The conceptual perspective presented here has its focus on hazard assessment and is grounded on the main findings and conclusions from a symposium and workshop held in Berlin in November 2021. It intends to provide further insights into how NAMs can be gradually integrated into chemical risk assessment aimed at protection of human health, until eventually the current paradigm is replaced by an animal-free "Next Generation Risk Assessment" (NGRA).
Collapse
Affiliation(s)
| | - Andrea Miccoli
- German Federal Institute for Risk Assessment (BfR), Berlin, Germany; National Research Council, Ancona, Italy
| | - Martin von Bergen
- Helmholtz Centre for Environmental Research-UFZ, Leipzig, Germany; German Centre for Integrative Biodiversity Research (iDiv) Halle-Jena-Leipzig, Leipzig, Germany; University of Leipzig, Faculty of Life Sciences, Institute of Biochemistry, Leipzig, Germany
| | | | - Albert Braeuning
- German Federal Institute for Risk Assessment (BfR), Berlin, Germany
| | - Wibke Busch
- Helmholtz Centre for Environmental Research-UFZ, Leipzig, Germany
| | - Christian Desaintes
- European Commission (EC), Directorate General for Research and Innovation (RTD), Brussels, Belgium
| | - Anne Gourmelon
- Organisation for Economic Cooperation and Development (OECD), Environment Directorate, Paris, France
| | | | - Joshua Harrill
- Center for Computational Toxicology and Exposure (CCTE), United States Environmental Protection Agency (US EPA), Durham, USA
| | - Thomas Hartung
- Center for Alternatives to Animal Testing (CAAT), Johns Hopkins Bloomberg School of Public Health Baltimore MD USA, CAAT-Europe, University of Konstanz, Konstanz, Germany
| | - Matthias Herzler
- German Federal Institute for Risk Assessment (BfR), Berlin, Germany
| | | | - Nicole Kleinstreuer
- NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), National Institute of Environmental Health Sciences (NIEHS), Durham, USA
| | - Marcel Leist
- CAAT‑Europe and Department of Biology, University of Konstanz, Konstanz, Germany
| | - Mirjam Luijten
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
| | | | - Oliver Poetz
- NMI Natural and Medical Science Institute at the University of Tuebingen, Reutlingen, Germany; SIGNATOPE GmbH, Reutlingen, Germany
| | | | - Rob Roggeband
- European Partnership for Alternative Approaches to Animal Testing (EPAA), Procter and Gamble Services Company NV/SA, Strombeek-Bever, Belgium
| | - Vera Rogiers
- Scientific Committee on Consumer Safety (SCCS), Vrije Universiteit Brussel (VUB), Brussels, Belgium
| | - Adrian Roth
- F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - Pascal Sanders
- Fougeres Laboratory, French Agency for Food, Environmental and Occupational Health and Safety (ANSES), Fougères, France France
| | - Russell S Thomas
- Center for Computational Toxicology and Exposure (CCTE), United States Environmental Protection Agency (US EPA), Durham, USA
| | | | | | | | - Andreas Luch
- German Federal Institute for Risk Assessment (BfR), Berlin, Germany
| | - Tewes Tralau
- German Federal Institute for Risk Assessment (BfR), Berlin, Germany
| |
Collapse
|
2
|
Pistollato F, Campia I, Daskalopoulos EP, Bernasconi C, Desaintes C, Di Virgilio S, Kyriakopoulou C, Whelan M, Deceuninck P. Gauging innovation and health impact from biomedical research: survey results and interviews with recipients of EU-funding in the fields of Alzheimer's disease, breast cancer and prostate cancer. Health Res Policy Syst 2023; 21:66. [PMID: 37386455 DOI: 10.1186/s12961-023-00981-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2022] [Accepted: 04/05/2023] [Indexed: 07/01/2023] Open
Abstract
Biomedical research on Alzheimer's disease (AD), breast cancer (BC) and prostate cancer (PC) has globally improved our understanding of the etiopathological mechanisms underlying the onset of these diseases, often with the goal to identify associated genetic and environmental risk factors and develop new medicines. However, the prevalence of these diseases and failure rate in drug development remain high. Being able to retrospectively monitor the major scientific breakthroughs and impact of such investment endeavors is important to re-address funding strategies if and when needed. The EU has supported research into those diseases via its successive framework programmes for research, technological development and innovation. The European Commission (EC) has already undertaken several activities to monitor research impact. As an additional contribution, the EC Joint Research Centre (JRC) launched in 2020 a survey addressed to former and current participants of EU-funded research projects in the fields of AD, BC and PC, with the aim to understand how EU-funded research has contributed to scientific innovation and societal impact, and how the selection of the experimental models may have underpinned the advances made. Further feedback was also gathered through in-depth interviews with some selected survey participants representative of the diverse pre-clinical models used in the EU-funded projects. A comprehensive analysis of survey replies, complemented with the information derived from the interviews, has recently been published in a Synopsis report. Here we discuss the main findings of this analysis and propose a set of priority actions that could be considered to help improving the translation of scientific innovation of biomedical research into societal impact.
Collapse
Affiliation(s)
- Francesca Pistollato
- European Commission, Joint Research Centre (JRC), Directorate F-Health, Consumers and Reference Materials, Via E. Fermi 2749, 21027, Ispra, VA, Italy
| | - Ivana Campia
- European Commission, Joint Research Centre (JRC), Directorate F-Health, Consumers and Reference Materials, Via E. Fermi 2749, 21027, Ispra, VA, Italy
| | - Evangelos P Daskalopoulos
- European Commission, Joint Research Centre (JRC), Directorate F-Health, Consumers and Reference Materials, Via E. Fermi 2749, 21027, Ispra, VA, Italy
| | - Camilla Bernasconi
- European Commission, Joint Research Centre (JRC), Directorate F-Health, Consumers and Reference Materials, Via E. Fermi 2749, 21027, Ispra, VA, Italy
| | | | - Sergio Di Virgilio
- European Commission, DG Research & Innovation (DG RTD), Brussels, Belgium
| | | | - Maurice Whelan
- European Commission, Joint Research Centre (JRC), Directorate F-Health, Consumers and Reference Materials, Via E. Fermi 2749, 21027, Ispra, VA, Italy
| | - Pierre Deceuninck
- European Commission, Joint Research Centre (JRC), Directorate F-Health, Consumers and Reference Materials, Via E. Fermi 2749, 21027, Ispra, VA, Italy.
| |
Collapse
|
3
|
Mori M, Benotmane MA, Vanhove D, van Hummelen P, Hooghe-Peters EL, Desaintes C. Effect of ionizing radiation on gene expression in CD4+ T lymphocytes and in Jurkat cells: unraveling novel pathways in radiation response. Cell Mol Life Sci 2016; 61:1955-64. [PMID: 15341025 DOI: 10.1007/s00018-004-4147-3] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
To better understand at the molecular level the effect of ionizing radiation in leukocytes, the global transcriptional response to X-ray irradiation was studied in human CD4+ T lymphocytes and in Jurkat cells. Microarray analysis performed on freshly isolated human CD4+ lymphocytes 8 h after an LD50 irradiation dose of 1 Gy revealed that out of 13,825 genes, 1084 were modulated more than 1.5-fold. The most strongly up-regulated genes were predominantly p53 targets. In contrast, exposure of the CD4+ T lymphocyte-derived Jurkat leukemic cell line (with no functional p53 gene) to an equivalent LD50 dose (0.5 Gy) induced a partly different and more limited set of genes. Interestingly, this set of genes belonged to the Rho and cytokine signaling pathways regulated by low-dose ionizing radiation.
Collapse
Affiliation(s)
- M Mori
- Laboratory of Radiobiology, Belgian Nuclear Research Centre (SCK.CEN), Boeretang, Mol, Belgium.
| | | | | | | | | | | |
Collapse
|
4
|
Bradley A, Anastassiadis K, Ayadi A, Battey JF, Bell C, Birling MC, Bottomley J, Brown SD, Bürger A, Bult CJ, Bushell W, Collins FS, Desaintes C, Doe B, Economides A, Eppig JT, Finnell RH, Fletcher C, Fray M, Frendewey D, Friedel RH, Grosveld FG, Hansen J, Hérault Y, Hicks G, Hörlein A, Houghton R, Hrabé de Angelis M, Huylebroeck D, Iyer V, de Jong PJ, Kadin JA, Kaloff C, Kennedy K, Koutsourakis M, Kent Lloyd KC, Marschall S, Mason J, McKerlie C, McLeod MP, von Melchner H, Moore M, Mujica AO, Nagy A, Nefedov M, Nutter LM, Pavlovic G, Peterson JL, Pollock J, Ramirez-Solis R, Rancourt DE, Raspa M, Remacle JE, Ringwald M, Rosen B, Rosenthal N, Rossant J, Ruiz Noppinger P, Ryder E, Schick JZ, Schnütgen F, Schofield P, Seisenberger C, Selloum M, Simpson EM, Skarnes WC, Smedley D, Stanford WL, Francis Stewart A, Stone K, Swan K, Tadepally H, Teboul L, Tocchini-Valentini GP, Valenzuela D, West AP, Yamamura KI, Yoshinaga Y, Wurst W. The mammalian gene function resource: the International Knockout Mouse Consortium. Mamm Genome 2012; 23:580-6. [PMID: 22968824 PMCID: PMC3463800 DOI: 10.1007/s00335-012-9422-2] [Citation(s) in RCA: 234] [Impact Index Per Article: 19.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2012] [Accepted: 07/20/2012] [Indexed: 11/16/2022]
Abstract
In 2007, the International Knockout Mouse Consortium (IKMC) made the ambitious promise to generate mutations in virtually every protein-coding gene of the mouse genome in a concerted worldwide action. Now, 5 years later, the IKMC members have developed high-throughput gene trapping and, in particular, gene-targeting pipelines and generated more than 17,400 mutant murine embryonic stem (ES) cell clones and more than 1,700 mutant mouse strains, most of them conditional. A common IKMC web portal (www.knockoutmouse.org) has been established, allowing easy access to this unparalleled biological resource. The IKMC materials considerably enhance functional gene annotation of the mammalian genome and will have a major impact on future biomedical research.
Collapse
Affiliation(s)
- Allan Bradley
- The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1HH UK
| | | | - Abdelkader Ayadi
- Institut Clinique de la Souris and Institut de Génétique et de Biologie Moléculaire et Cellulaire, 67404 Illkirch Cedex, France
| | - James F. Battey
- National Institute on Deafness and Other Communication Disorders (NIH), Bethesda, MD 20892 USA
| | - Cindy Bell
- Genome Canada, Ottawa, ON K2P 1P1 Canada
| | - Marie-Christine Birling
- Institut Clinique de la Souris and Institut de Génétique et de Biologie Moléculaire et Cellulaire, 67404 Illkirch Cedex, France
| | - Joanna Bottomley
- The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1HH UK
| | - Steve D. Brown
- Mammalian Genetics Unit, MRC Harwell, Harwell Science and Innovation Campus, Oxfordshire, OX11 0RD UK
| | - Antje Bürger
- Institute of Developmental Genetics, Helmholtz Zentrum München, Technische Universität München, 85764 Neuherberg, Germany
| | | | - Wendy Bushell
- The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1HH UK
| | | | - Christian Desaintes
- Infectious Diseases and Public Health, European Commission, DG Research & Innovation, 1049 Brussels, Belgium
| | - Brendan Doe
- Istituto di Biologia Cellulare, Consiglio Nazionale delle Ricerche (CNR), Monterotondo-Scalo, 00015 Rome, Italy
| | - Aris Economides
- Velocigene Division, Regeneron Pharmaceuticals Inc., Tarrytown, NY 10591 USA
| | | | - Richard H. Finnell
- The Texas A&M Institute for Genomic Medicine, College Station, TX 77843-4485 USA
- University of Texas at Austin, Austin, TX 78712 USA
| | | | - Martin Fray
- Mammalian Genetics Unit, MRC Harwell, Harwell Science and Innovation Campus, Oxfordshire, OX11 0RD UK
| | - David Frendewey
- Velocigene Division, Regeneron Pharmaceuticals Inc., Tarrytown, NY 10591 USA
| | - Roland H. Friedel
- Institute of Developmental Genetics, Helmholtz Zentrum München, Technische Universität München, 85764 Neuherberg, Germany
- Icahn Medical Institute, The Mount Sinai Hospital, New York, NY 10029 USA
| | - Frank G. Grosveld
- Department of Cell Biology, Center of Biomedical Genetics, Erasmus University Medical Center, 3015 GE Rotterdam, The Netherlands
| | - Jens Hansen
- Institute of Developmental Genetics, Helmholtz Zentrum München, Technische Universität München, 85764 Neuherberg, Germany
| | - Yann Hérault
- Institut Clinique de la Souris and Institut de Génétique et de Biologie Moléculaire et Cellulaire, 67404 Illkirch Cedex, France
| | - Geoffrey Hicks
- Manitoba Institute of Cell Biology, University of Manitoba, Winnipeg, MB R3E OV9 Canada
| | - Andreas Hörlein
- Institute of Developmental Genetics, Helmholtz Zentrum München, Technische Universität München, 85764 Neuherberg, Germany
| | - Richard Houghton
- The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1HH UK
| | | | - Danny Huylebroeck
- Department of Development and Regeneration, Faculty of Medicine, University of Leuven (KU Leuven), 3000 Leuven, Belgium
| | - Vivek Iyer
- The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1HH UK
| | - Pieter J. de Jong
- Children’s Hospital Oakland Research Institute (CHORI), Oakland, CA 94609 USA
| | | | - Cornelia Kaloff
- Institute of Developmental Genetics, Helmholtz Zentrum München, Technische Universität München, 85764 Neuherberg, Germany
| | - Karen Kennedy
- The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1HH UK
| | - Manousos Koutsourakis
- The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1HH UK
| | - K. C. Kent Lloyd
- Mouse Biology Program, School of Veterinary Medicine, University of California, Davis, CA 95616 USA
| | - Susan Marschall
- Institute of Experimental Genetics, Helmholtz Zentrum München, 85764 Neuherberg, Germany
| | - Jeremy Mason
- The Jackson Laboratory, Bar Harbor, ME 04609 USA
| | - Colin McKerlie
- Research Institute, The Hospital for Sick Children, SickKids Foundation, Toronto, ON M5G2L3 Canada
| | - Michael P. McLeod
- The Texas A&M Institute for Genomic Medicine, College Station, TX 77843-4485 USA
| | - Harald von Melchner
- Department of Molecular Haematology, University of Frankfurt Medical School, 60590 Frankfurt am Main, Germany
| | - Mark Moore
- National Institutes of Health, Bethesda, MD 20205 USA
| | - Alejandro O. Mujica
- The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1HH UK
- Velocigene Division, Regeneron Pharmaceuticals Inc., Tarrytown, NY 10591 USA
| | - Andras Nagy
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Joseph and Wolf Lebovic Health Complex, Toronto, ON M5G 1X5 Canada
| | - Mikhail Nefedov
- Children’s Hospital Oakland Research Institute (CHORI), Oakland, CA 94609 USA
| | - Lauryl M. Nutter
- Research Institute, The Hospital for Sick Children, SickKids Foundation, Toronto, ON M5G2L3 Canada
| | - Guillaume Pavlovic
- Institut Clinique de la Souris and Institut de Génétique et de Biologie Moléculaire et Cellulaire, 67404 Illkirch Cedex, France
| | | | - Jonathan Pollock
- Division of Basic Neuroscience and Research, National Institute of Drug Abuse (NIDA), Bethesda, MD 20892-0001 USA
| | - Ramiro Ramirez-Solis
- The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1HH UK
| | - Derrick E. Rancourt
- Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, AB T2N 1N4 Canada
| | - Marcello Raspa
- Istituto di Biologia Cellulare, Consiglio Nazionale delle Ricerche (CNR), Monterotondo-Scalo, 00015 Rome, Italy
| | - Jacques E. Remacle
- Infectious Diseases and Public Health, European Commission, DG Research & Innovation, 1049 Brussels, Belgium
| | | | - Barry Rosen
- The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1HH UK
| | - Nadia Rosenthal
- European Molecular Biology Laboratory (EMBL), Monterotondo, 00015 Rome, Italy
| | - Janet Rossant
- Research Institute, The Hospital for Sick Children, SickKids Foundation, Toronto, ON M5G2L3 Canada
| | - Patricia Ruiz Noppinger
- Centre for Cardiovascular Research, Department of Vertebrate Genomics, Charité, 10115 Berlin, Germany
| | - Ed Ryder
- The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1HH UK
| | - Joel Zupicich Schick
- Institute of Developmental Genetics, Helmholtz Zentrum München, Technische Universität München, 85764 Neuherberg, Germany
| | - Frank Schnütgen
- Department of Molecular Haematology, University of Frankfurt Medical School, 60590 Frankfurt am Main, Germany
| | - Paul Schofield
- Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, CB2 3EG UK
| | - Claudia Seisenberger
- Institute of Developmental Genetics, Helmholtz Zentrum München, Technische Universität München, 85764 Neuherberg, Germany
| | - Mohammed Selloum
- Institut Clinique de la Souris and Institut de Génétique et de Biologie Moléculaire et Cellulaire, 67404 Illkirch Cedex, France
| | - Elizabeth M. Simpson
- Department of Medical Genetics, Centre for Molecular Medicine and Therapeutics at the Child & Family Research Institute, University of British Columbia, Vancouver, BC V5Z 4H4 Canada
| | - William C. Skarnes
- The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1HH UK
| | - Damian Smedley
- The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1HH UK
- European Bioinformatics Institute (EBI), Hinxton, Cambridge, CB10 1ST UK
| | | | - A. Francis Stewart
- Biotechnology Center (BIOTEC) of the Technische Universität Dresden, 01307 Dresden, Germany
| | - Kevin Stone
- The Jackson Laboratory, Bar Harbor, ME 04609 USA
| | - Kate Swan
- Genome Canada, Ottawa, ON K2P 1P1 Canada
| | | | - Lydia Teboul
- Mammalian Genetics Unit, MRC Harwell, Harwell Science and Innovation Campus, Oxfordshire, OX11 0RD UK
| | | | - David Valenzuela
- Velocigene Division, Regeneron Pharmaceuticals Inc., Tarrytown, NY 10591 USA
| | - Anthony P. West
- The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1HH UK
| | - Ken-ichi Yamamura
- Division of Developmental Genetics, Center for Animal Resources and Development, Institute of Resource Development and Analysis, Kumamoto University, Kumamoto, 860-0811 Japan
| | - Yuko Yoshinaga
- Children’s Hospital Oakland Research Institute (CHORI), Oakland, CA 94609 USA
| | - Wolfgang Wurst
- Institute of Developmental Genetics, Helmholtz Zentrum München, Technische Universität München, 85764 Neuherberg, Germany
- Max-Planck-Institute of Psychiatry, 80804 Munich, Germany
- Deutsches Zentrum fuer Neurodegenerative Erkrankungen e.V. (DZNE) Site Munich, 80336 Munich, Germany
| |
Collapse
|
5
|
Kollias G, Papadaki P, Apparailly F, Vervoordeldonk MJ, Holmdahl R, Baumans V, Desaintes C, Di Santo J, Distler J, Garside P, Hegen M, Huizinga TWJ, Jüngel A, Klareskog L, McInnes I, Ragoussis I, Schett G, Hart B', Tak PP, Toes R, van den Berg W, Wurst W, Gay S. Animal models for arthritis: innovative tools for prevention and treatment. Ann Rheum Dis 2011; 70:1357-62. [PMID: 21628308 DOI: 10.1136/ard.2010.148551] [Citation(s) in RCA: 78] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
The development of novel treatments for rheumatoid arthritis (RA) requires the interplay between clinical observations and studies in animal models. Given the complex molecular pathogenesis and highly heterogeneous clinical picture of RA, there is an urgent need to dissect its multifactorial nature and to propose new strategies for preventive, early and curative treatments. Research on animal models has generated new knowledge on RA pathophysiology and aetiology and has provided highly successful paradigms for innovative drug development. Recent focus has shifted towards the discovery of novel biomarkers, with emphasis on presymptomatic and emerging stages of human RA, and towards addressing the pathophysiological mechanisms and subsequent efficacy of interventions that underlie different disease variants. Shifts in the current paradigms underlying RA pathogenesis have also led to increased demand for new (including humanised) animal models. There is therefore an urgent need to integrate the knowledge on human and animal models with the ultimate goal of creating a comprehensive 'pathogenesis map' that will guide alignment of existing and new animal models to the subset of disease they mimic. This requires full and standardised characterisation of all models at the genotypic, phenotypic and biomarker level, exploiting recent technological developments in 'omics' profiling and computational biology as well as state of the art bioimaging. Efficient integration and dissemination of information and resources as well as outreach to the public will be necessary to manage the plethora of data accumulated and to increase community awareness and support for innovative animal model research in rheumatology.
Collapse
Affiliation(s)
- George Kollias
- Biomedical Sciences Research Center Alexander Fleming,Institute of Immunology, Vari-Athens, Greece.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Fabre KM, Ramaiah L, Dregalla RC, Desaintes C, Weil MM, Bailey SM, Ullrich RL. Murine Prkdc polymorphisms impact DNA-PKcs function. Radiat Res 2011; 175:493-500. [PMID: 21265624 DOI: 10.1667/rr2431.1] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Polymorphic variants of DNA repair genes can increase the carcinogenic potential of exposure to ionizing radiation. Two single nucleotide polymorphisms (SNPs) in Prkdc, the gene encoding the DNA-dependent protein kinase catalytic subunit (DNA-PKcs), have been identified in BALB/c mice and linked to reduced DNA-PKcs activity and mammary cancer susceptibility. We examined three additional mouse strains to better define the roles of the BALB/c Prkdc SNPs (R2140C and M3844V). One is a congenic strain (C.B6) that has the C57BL/6 Prkdc allele on a BALB/c background, and the other is a congenic strain (B6.C) that has the BALB/c variant Prkdc allele on a C57BL/6 background. We also examined the LEWES mouse strain, which possesses only one of the BALB/c Prkdc SNPs (M3844V). Our results demonstrate that both Prkdc SNPs are responsible for deficient DNA-PKcs protein expression, DNA repair and telomere function, while the LEWES SNP affects only DNA-PKcs expression and repair capacity. These studies provide insight into the separation of function between the two BALB/c SNPs as well as direct evidence that SNPs positioned within Prkdc can significantly influence DNA-PKcs function involving DNA repair capacity, telomere end-capping, and potentially cancer susceptibility.
Collapse
Affiliation(s)
- Kristin M Fabre
- Department of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, Colorado 80523, USA
| | | | | | | | | | | | | |
Collapse
|
7
|
Sander M, Begley TJ, Desaintes C, Gavin AC, Pelroy R, Pothof J, Shiloh Y, van Gent D, Van Houten B, Yaffe M, Mullenders L. 3rd US-EU workshop: systems level understanding of DNA damage responses. Mutat Res 2010; 692:53-60. [PMID: 20727903 PMCID: PMC2948618 DOI: 10.1016/j.mrfmmm.2010.07.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2010] [Accepted: 07/30/2010] [Indexed: 05/29/2023]
Abstract
The 3rd US-EU Workshop on systems level understanding of DNA damage responses was held from March 30 to April 1, 2009 in Egmond aan Zee, The Netherlands. Objectives of the workshop were (1) to assess the current science of the DDR, in particular network level responses to chemotherapeutic and environmentally induced DNA damage; and (2) to establish the basis for a reciprocal scientific exchange program between the EU and US in the relevant areas of DDR research. Here, we report the highlights of the meeting program and conclude that this third meeting in 2009 refined the role of DDR networks in human disease.
Collapse
Affiliation(s)
- Miriam Sander
- University at Albany, SUNY, Rensselaer, New York, NY 12144-3456, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Abstract
Recognising the crucial role of model organisms in exploring the causes of human disease and in developing safe treatments, the European Commission has invested euro180 million in collaborative research projects on model organisms since 2002. Further financial support is planned for the future. Projects supported by the European Commission are playing an important role in structuring the research landscape in Europe and creating the knowledge base to understand health and disease. Furthermore, they are generating important and freely available data and/or animal resources that will catalyse progress in biomedical research. This paper focuses on animal model organisms and includes the rodents, mouse and rat, other vertebrates such as zebrafish and frog, and also invertebrates such as nematodes. Research on other model organisms, including yeast, bacteria and plants, is also being supported and this is providing knowledge on basic cellular and molecular processes, as well as on host-microorganism interactions.
Collapse
Affiliation(s)
- Christian Desaintes
- European Commission, DG Research Health, Genomics and Systems Biology, CDMA-1/8, B-1049 Brussels, Belgium.
| |
Collapse
|
9
|
Van Bressem MF, Cassonnet P, Rector A, Desaintes C, Van Waerebeek K, Alfaro-Shigueto J, Van Ranst M, Orth G. Genital warts in Burmeister's porpoises: characterization of Phocoena spinipinnis papillomavirus type 1 (PsPV-1) and evidence for a second, distantly related PsPV. J Gen Virol 2007; 88:1928-1933. [PMID: 17554024 DOI: 10.1099/vir.0.82694-0] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
We identified sequences from two distantly related papillomaviruses in genital warts from two Burmeister's porpoises, including a PV antigen-positive specimen, and characterized Phocoena spinipinnis papillomavirus type 1 (PsPV-1). The PsPV-1 genome comprises 7879 nt and presents unusual features. It lacks an E7, an E8 and a bona fide E5 open reading frame (ORF) and has a large E6 ORF. PsPV-1 L1 ORF showed the highest percentage of nucleotide identity (54-55 %) with human papillomavirus type 5, bovine papillomavirus type 3 (BPV-3) and Tursiops truncatus papillomavirus type 2 (TtPV-2). This warrants the classification of PsPV-1 as the prototype of the genus Omikronpapillomavirus. PsPV-1 clustered with TtPV-2 in the E6 and E1E2 phylogenetic trees and with TtPV-2 and BPV-3 in the L2L1 tree. This supports the hypothesis that PV evolution may not be monophyletic across all genes.
Collapse
Affiliation(s)
- Marie-Françoise Van Bressem
- Cetacean Conservation Medicine Group (CMED), CEPEC/Museo de Delfines, Waldspielplatz 11, 82319 Starnberg, Germany
| | - Patricia Cassonnet
- Département de Virologie, Institut Pasteur, 25 rue du Dr Roux, 75724 Paris Cedex 15, France
| | - Annabel Rector
- Laboratory of Clinical and Epidemiological Virology, Rega Institute for Medical Research, University of Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium
| | | | - Koen Van Waerebeek
- Cetacean Conservation Medicine Group (CMED), CEPEC/Museo de Delfines, Waldspielplatz 11, 82319 Starnberg, Germany
| | | | - Marc Van Ranst
- Laboratory of Clinical and Epidemiological Virology, Rega Institute for Medical Research, University of Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium
| | - Gérard Orth
- Département de Virologie, Institut Pasteur, 25 rue du Dr Roux, 75724 Paris Cedex 15, France
| |
Collapse
|
10
|
Teissier S, Ben Khalifa Y, Mori M, Pautier P, Desaintes C, Thierry F. A new E6/P63 pathway, together with a strong E7/E2F mitotic pathway, modulates the transcriptome in cervical cancer cells. J Virol 2007; 81:9368-76. [PMID: 17582001 PMCID: PMC1951466 DOI: 10.1128/jvi.00427-07] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Cervical carcinoma is associated with certain types of human papillomaviruses expressing the E6 and E7 oncogenes, which are involved in carcinogenesis through their interactions with the p53 and pRB pathways, respectively. A critical event on the path to malignant transformation is often manifested by the loss of expression of the viral E2 transcription factor due to the integration into the host genome of the viral DNA. Using microarrays, we have previously shown that reintroduction of a functional E2 in the HeLa cervical carcinoma cell line activates a cluster of p53 target genes while at the same time severely repressing a group of E2F target genes. In the present study, using new high-density microarrays containing more than 22,000 human cDNA sequences, we identified a novel p63 pathway among E2-activated genes and 38 new mitotic genes repressed by E2. We then sought to determine the pathways through which these genes were modulated and used an approach that relies on small interfering RNA to demonstrate that the p63 target genes were activated through silencing of the E6/E6AP pathway while the mitotic genes were mainly repressed through E7 silencing. Importantly, a subset of the mitotic genes was shown to be significantly induced in biopsies of stage IV cervical cancers, which points to a prominent E7 pathway in cervical carcinoma.
Collapse
Affiliation(s)
- Sébastien Teissier
- Unité Expression Génétique et Maladies, CNRS FRE 2850, Institut Pasteur, 25 rue du Dr. Roux, 75724 Paris cedex 15, France
| | | | | | | | | | | |
Collapse
|
11
|
Sander M, Desaintes C, Ferro W, Mullenders L, Vrieling H, Pelroy R, Van Houten B, Wallace S. Meeting report. Second EU-US workshop on systems level understanding of DNA damage responses. Mutat Res 2006; 599:178-204. [PMID: 16929562 DOI: 10.1016/j.mrfmmm.2006.05.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- Miriam Sander
- Page One Editorial Services, 390 5th St., Boulder, CO 80304, USA
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Mori M, Benotmane MA, Verheyde J, Van Hummelen P, Hooghe-Peters EL, Desaintes C. Gene Expression Induced by X-ray Irradiation in Human Blood Cell Lines. Ann N Y Acad Sci 2006; 1010:339-41. [PMID: 15033747 DOI: 10.1196/annals.1299.061] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The response to X-ray irradiation of three different human hematopoietic cell lines originating from T (Jurkat), B (Raji), and promyelocytic (HL60) leukemia was analyzed. The survival after irradiation differed among the three cell lines, with Jurkat cells being the most vulnerable and HL60 being the least sensitive. The profile of gene expression was studied with the microarray technique in both Jurkat and HL60 cell lines. Out of the 13,800 different genes spotted on microarrays, very few genes (<0.5%) appeared to be induced more than 2-fold or repressed more than 2.5-fold in both cell lines.
Collapse
Affiliation(s)
- M Mori
- Laboratory of Radiobiology, Belgian Nuclear Research Center (SCK-CEN), B-2400 Mol, Belgium.
| | | | | | | | | | | |
Collapse
|
13
|
Abstract
Human lymphocyte subpopulations differ in their cellular responses to ionizing radiation. To shed light on the molecular basis of this effect, we characterized the transcriptional response to 1 Gy X-rays of CD4+ T lymphocytes. Of 18,433 genes tested, 102 were modulated more than 1.5-fold. The majority of the strongly activated genes were p53 targets involved in DNA repair and apoptosis. The expression of three of these genes was further tested by quantitative RT-PCR in lymphocyte subpopulations [CD4+ and CD8+ T, CD19+ B, CD56+ natural killer cells and peripheral blood lymphocytes (PBLs)] from ten adult donors. In contrast to DDB2, TNFRSF10B and BAX were differentially modulated among the subpopulations and the PBLs, being more activated in irradiated CD19+ B and CD8+ T lymphocytes. The level of BAX activation in the various subpopulations correlated with the sensitivity of the cells to radiation, suggesting its possible role in the differential radiosensitivity of hematopoietic cell subsets.
Collapse
Affiliation(s)
- M Mori
- Laboratory of Radiobiology and Microbiology, Belgian Nuclear Research Centre (SCK.CEN), Boeretang 200, Mol 2400, Belgium.
| | | | | | | | | |
Collapse
|
14
|
Mori M, Desaintes C. Gene expression in response to ionizing radiation: an overview of molecular features in hematopoietic cells. J BIOL REG HOMEOS AG 2004; 18:363-71. [PMID: 15786706] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Abstract
We review the molecular mechanisms involved in response to ionizing radiation in various hematopoietic cell types. First, a general overview of the radiation induced cell signaling molecules in mammals is given. The importance of highly conserved kinases, such as ATM and ATR, as well as the p53 protein for maintaining the genome stability is highlighted. Next, particular attention is given to radiation-induced gene expression in the hematopoietic system. For some hemopoietic cell subpopulations, recent data are provided which might explain the differential radiosensitivity of these cells. Finally, radiation-induced cytokines are reviewed, as they affect the global response to radiation.
Collapse
Affiliation(s)
- M Mori
- Laboratory of Radiobiology, Belgian Nuclear Research Centre (SCK-CEN), Mol, Belgium.
| | | |
Collapse
|
15
|
Sander M, Desaintes C, Pelroy R, Ferro W, Van Houten B, Amundson S, Lehmann A, Mullenders L, Sansone SA, Stambrook P, van Zeeland B, Vrieling H, Wennborg A. Meeting report: EU-US Workshop on Molecular Signatures of DNA Damage-Induced Stress Responses. Cortona, Italy, 26-30 September 2003. Mutat Res 2004; 550:145-81. [PMID: 15228042 DOI: 10.1016/j.mrfmmm.2004.02.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- Miriam Sander
- Page One Editorial Services, 403 Carolina Circle, Durham, NC 27707-2252, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Abstract
More than 90% of cervical carcinomas are associated with human papillomavirus (HPV) infection. The two viral oncogenes E6 and E7 play a major role in transforming the cells by disrupting p53- and pRb-dependent cell cycle checkpoints. A hallmark of HPV-associated cervical carcinoma is loss of the expression of the viral E2 protein, often by disruption of E2-encoding gene. We showed previously that reintroduction of E2 in HPV18-associated cervical carcinoma cells induces cell cycle arrest in G(1) because of the transcriptional repression of the viral oncogenes E6 and E7 and concomitant reactivation of the p53 and pRb pathways. Here we describe global gene profiling of HeLa cells expressing different HPV18 E2 mutants to study the effects of repression of the viral oncogenes. We identified 128 genes transcriptionally regulated by the viral oncogenes in cervical carcinoma. Surprisingly, E2 repressed a subset of E2F-regulated mitotic genes in an E6/E7-dependent pathway. This was corroborated by the observation that E2 delayed mitotic progression, suggesting the involvement of a mitotic pathway in HPV carcinogenesis. These mitotic genes constitute an as yet unrecognized set of genes, which were also found deregulated in other HPV-associated cervical carcinoma cell lines and therefore represent new targets for both diagnosis and therapeutic approaches in cervical cancer.
Collapse
Affiliation(s)
- Françoise Thierry
- Unit of Gene Expression and Diseases, Unité de Recherche Associée 1644 of Centre National de la Recherche Scientifique, Institut Pasteur, Paris, France.
| | | | | | | | | | | |
Collapse
|
17
|
Jacquet P, Buset J, Vankerkom J, Baatout S, de Saint-Georges L, Schoonjans W, Desaintes C. Mouse one-cell embryos undergoing a radiation-induced G2 arrest may re-enter S-phase in the absence of cytokinesis. Can J Physiol Pharmacol 2002; 80:618-24. [PMID: 12182319 DOI: 10.1139/y02-093] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
PCC (premature chromosome condensation) can be used for visualizing and scoring damage induced by radiation in the chromatin of cells undergoing a G1 or G2 arrest. A method involving the fusion of irradiated single embryonic cells with single MI oocytes was used to induce PCC in mouse zygotes of the BALB/c strain, which suffer a drastic G2 arrest after X-irradiation (dose used 2.5 Gy). Other G2-arrested embryos were exposed in vitro to the phosphatase inhibitor calyculin A. Both methods furnished excellent chromosome preparations of the G2-arrested embryos. The mean number of chromosome fragments did not change significantly during G2 arrest, suggesting that zygotes of this strain are unable to repair DNA damage leading to such aberrations. Forty to fifty percent of the irradiated embryos were unable to cleave after G2 arrest and remained blocked at the one-cell stage for a few days before dying. PCC preparations obtained from such embryos suggested that about 30% of them had undergone a late mitosis not followed by cytokinesis and had entered a new DNA synthesis. These results are discussed in the light of recent observations in irradiated human cells deficient in the p53/14-3-3sigma pathway.
Collapse
Affiliation(s)
- P Jacquet
- Department of Radioprotection, CEN/SCK, Mol, Belgium.
| | | | | | | | | | | | | |
Collapse
|
18
|
Baatout S, Jacquet P, Michaux A, Buset J, Vankerkom J, Derradji H, Yan J, von Suchodoletz H, de Saint-Georges L, Desaintes C, Mergeay M. Developmental abnormalities induced by X-irradiation in p53 deficient mice. In Vivo 2002; 16:215-21. [PMID: 12182118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/26/2023]
Abstract
In order to assess the influence of p53 inactivation on radiation-induced developmental effects, male mice heterozygous for the wild-type p53 allele (mimicking the human Li-Fraumeni syndrome) were crossed with C57BL females, and their heterozygous p53+/- progeny were mated with each other to obtain p53+/-, p53-/- and p53+/+ embryos. Pregnant females were X-irradiated with 0.5 Gy on days 1 (pre-implantation period), 8 or 11 (organogenesis period) of gestation. Dissection of the pregnant females occurred on day 19 of gestation. The p53 genotype of the foetuses was determined by PCR from small pieces of soft tissues. Exencephaly was the only external malformation found in the control group. It affected essentially p53-/- female foetuses. A number of p53+/- and p53+/- control foetuses also showed dwarfism, or underdevelopment. In the group irradiated on day 1, the frequency of abnormal foetuses was, paradoxically, lower than that found in the control group. As in that group, exencephaly and dwarfism constituted the only anomalies that were found. Exencephaly affected only homozygous p53-/- females, while dwarfism concerned either p53-/- or p53+/- foetuses, with a majority of females. Irradiation on day 8 of gestation induced a significant increase in the frequency of abnormal foetuses, compared to the control group. Various malformations were observed in addition to exencephaly, including gastroschisis, polydactyly, cephalic oedema and cleft palate. All malformed foetuses were either homozygous p53-/- or heterozygous p53+/- while most affected foetuses were females, as was the case for dwarf individuals. Irradiation on day 11 did not cause an increase in the frequency of abnormal foetuses, in comparison with the controls. However, a large spectrum of external malformations was again noticed, as in the group irradiated on day 8. All affected foetuses were homozygous p53-/- and there were slightly more abnormal females than males (3 out of 5). No dwarfs were found in this group. Overall, these results confirm the importance of the p53 tumour-suppressor protein for normal embryonic development. They clearly show that homozygous p53-/- (or heterozygous p53+/- to a lesser extent) foetuses are more at risk for radiation-induction of external malformations during the organogenesis period, and that the risk of developing such malformations is much higher for females than for males. In contrast to results published very recently by others, we found that malformed foetuses resulting from an X-irradiation with a low-dose during the highly sensitive period of gastrulation are able to survive to birth.
Collapse
Affiliation(s)
- Sarah Baatout
- Laboratory of Radiobiology, Belgian Nuclear Research Centre, SCK-CEN, Boeretang 200, B-2400 Mol, Belgium.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Jacquet P, Buset J, Vankerkom J, Baatout S, de Saint-Georges L, Baugnet-Mahieu L, Desaintes C. Radiation-induced chromosome aberrations in guinea-pig growing oocytes, and their relation to follicular atresia. Mutat Res 2001; 473:249-54. [PMID: 11166041 DOI: 10.1016/s0027-5107(00)00153-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The female guinea-pig has been shown to represent a good model to investigate the genetic hazard of ionizing radiation in humans. The sensitivity of the guinea-pig oocytes to radiation-induced chromosome aberrations was, therefore, studied at different stages of oocyte and follicular growth. The sensitivity of oocytes enclosed in small follicles (15 weeks before ovulation) was found to be low and comparable to that of immature oocytes present at birth. The sensitivity of growing oocytes remained low and almost constant until 3 weeks before ovulation, from which time it began to increase. The most dramatic increase of sensitivity occurred during the last week preceding ovulation: about 90% of oocytes X-irradiated with 4Gy, 2 days before ovulation showed one or more chromatid interchanges, as compared to 20% for those irradiated with the same dose 1 week earlier. A comparison of our results with those found by others in the mouse shows that considerable differences of sensitivity exist between oocytes of these two species irradiated at similar stages of development. The possible reasons for these differences are discussed.
Collapse
Affiliation(s)
- P Jacquet
- Laboratory of Radiobiology, Department of Radioprotection, CEN/SCK, Boeretang 200, B-2400 Mol, Belgium.
| | | | | | | | | | | | | |
Collapse
|
20
|
Baatout S, Jacquet P, Michaux A, Buset J, Desaintes C. Histone H1 kinase activity in ovulated oocytes. Anticancer Res 1999; 19:5117-8. [PMID: 10697519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
The level of kinase activity of cdkl is known to be high during metaphase of the two meioses. In this experiment, histone H1 kinase activity (which is known to reflect cdk1 activity) was assayed in BALB/c mouse ovulated oocytes at various timepoints after ovulation. Histone H1 kinase activity in ovulated oocytes was stable up to 37 hours after ovulation. After that time, histone H1 kinase activity significantly decreased suggesting that cdkl might be degraded after this period of time if the ovulated oocyte is not fertilised.
Collapse
Affiliation(s)
- S Baatout
- Laboratory of Radiobiology, Belgian Nuclear Energy Study Center, CEN-SCK, Mol, Belgium.
| | | | | | | | | |
Collapse
|
21
|
Reyners H, Gianfelici de Reyners E, Yan J, De Saint-Georges L, Desaintes C. Delayed effects of prenatal low-dose irradiation in the white matter of the rat brain. Int J Radiat Biol 1999; 75:1327-34. [PMID: 10549610 DOI: 10.1080/095530099139494] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
PURPOSE This study is part of a general search for the anatomical bases of the severe mental retardation syndrome caused by prenatal irradiation. More specifically, it seeks reasons for the high radiosensitivity of a white matter area, the cingulum of the corpus callosum. MATERIALS AND METHODS Pregnant primiparous Wistar rats were exposed to X-rays at 12, 13, 14 or 15 days of gestation (E12, E13, E14 or E15) with single low doses of 180 mGy. A high dose of 500 mGy was given at E15 for a complementary study. The brains of the female offspring were collected at 1 and 3 months of age. The affinity of osmium tetroxide for the white matter was used to recognize and quantify cingulum areas in a series of coronal sections made at different positions along the antero-posterior axis of the brains. RESULTS A 180 mGy dose of X-rays caused an atrophy of the cingulum; the effect was particularly significant in the 1-month-old brains after an exposure at E13 or at E14, and increased in the 3-month-old animals exposed at E15. The axonal size distribution was unchanged in the 3-month-old cingulums treated with 500 mGy at E15. CONCLUSIONS The atrophy of the cingulum is due to a loss of axons, which are abundant in this area. As a consequence of axon loss, a reduction of the postnatal myelination enhances the volumetric decrease of the cingulum at 3 months of age.
Collapse
Affiliation(s)
- H Reyners
- CEN-SCK, Unit of Radiobiology, Mol, Belgium
| | | | | | | | | |
Collapse
|
22
|
Abstract
We have previously shown that expression of the papillomavirus E2 protein in HeLa cells induces p53 accumulation and causes both cell cycle arrest and apoptosis. In contrast to growth arrest, onset of apoptosis was not correlated with an increase of p53 transcriptional activity. In the present study, we conducted biochemical and genetic experiments in order to determine whether E2-induced apoptosis was independent of p53 induction. We showed that E2 did not alter the transcription of Bax, a known p53-activated cell death inducer. The time course of apoptotic cell death preceded p53 induction by several hours. Overexpression of the HPV18 E6 oncogene prevented E2-mediated p53 accumulation, but did not alter the rate of cell death. Finally, point mutants of the HPV18 E2 transactivation domain induced apoptosis, although they were unable to induce high p53 accumulation or cell cycle arrest. In addition, the results obtained with these mutants indicated that both transcriptional activation and replication functions of E2 were dispensable for the induction of cell death. These observations show that E2-induced apoptosis is an early event, independent of p53 accumulation and unrelated to downstream p53-dependent transcriptional events.
Collapse
Affiliation(s)
- C Desaintes
- Unité des virus oncogènes, département des biotechnologies, URA 1644 du CNRS, Institut Pasteur, 25 rue du Dr Roux, 75724 Paris, cedex 15, Paris, France
| | | | | | | | | |
Collapse
|
23
|
Demeret C, Desaintes C, Yaniv M, Thierry F. Different mechanisms contribute to the E2-mediated transcriptional repression of human papillomavirus type 18 viral oncogenes. J Virol 1997; 71:9343-9. [PMID: 9371593 PMCID: PMC230237 DOI: 10.1128/jvi.71.12.9343-9349.1997] [Citation(s) in RCA: 87] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Transcription of the human papillomavirus type 18 (HPV18) E6 and E7 oncogenes is repressed by the viral E2 protein. In C33 cells, we have previously shown that of the four E2 binding sites (E2 BS) present in the HPV18 long control region (LCR), only the binding site adjacent to the TATA box (E2 BS 1) was involved in E2-mediated repression. In the present study, we sought to determine whether this phenomenon was conserved in other cell lines. We first showed that all three E2 BS proximal to the P105 promoter were required for full repression of its activity in HeLa and HaCaT cells. Repression by E2 at E2 BS 2 occurred through the displacement of Sp1. Second, a truncated E2 product, lacking the N-terminal transactivation domain, repressed transcription more efficiently than the full-length protein. Repression was abolished when the N-terminal domain of E2 was replaced by the activation domain of VP16. The VP16-E2 chimeric protein could activate transcription from an LCR mutated in its TATA box. DNA-protein binding studies showed that E2 associates with its four binding sites in the LCR with similar affinities. However, challenge of such complexes with excess binding sites demonstrated that interaction with E2 BS 4 was the most stable while interaction with E2 BS 1 was the least stable. Furthermore, complexes with the full-length E2 were less stable than those formed with the N-terminally truncated protein.
Collapse
Affiliation(s)
- C Demeret
- Département des Biotechnologies, URA 1644 du CNRS, Institut Pasteur, Paris, France
| | | | | | | |
Collapse
|
24
|
Abstract
The papillomavirus E2 protein plays a central role in the viral life cycle as it regulates both transcription and replication of the viral genome. In this study, we showed that transient expression of bovine papillomavirus type 1 or human papillomavirus type 18 (HPV18) E2 proteins in HeLa cells activated the transcriptional activity of p53 through at least two pathways. The first one involved the binding of E2 to its recognition elements located in the integrated viral P105 promoter. E2 binding consequently repressed transcription of the endogenous HPV18 E6 oncogene, whose product has been shown previously to promote p53 degradation. The second pathway did not require specific DNA binding by E2. Expression of E2 induced drastic physiological changes, as evidenced by a high level of cell death by apoptosis and G1 arrest. Overexpression of a p53 trans-dominant-negative mutant abolished both E2-induced p53 transcriptional activation and E2-mediated G1 growth arrest, but showed no effect on E2-triggered apoptosis. These results suggest that the effects of E2 on cell cycle progression and cell death follow distinct pathways involving two different functions of p53.
Collapse
Affiliation(s)
- C Desaintes
- Département des Biotechnologies, URA 1644 du CNRS, Institut Pasteur, Paris, France
| | | | | | | | | |
Collapse
|
25
|
Abstract
Hallmarks of HPV infection include a restricted tropism for human epithelial cells and a viral life cycle tightly linked to the differentiation program of the host keratinocyte. This particular viral cycle has hampered the study of the HPV vegetative life cycle for decades, due to the lack of suitable in-vitro culture conditions. The tissue and differentiation dependence seems to be dictated by viral transcription rather than viral DNA replication. Indeed, viral transcription is restricted to epithelial cells of human origin, more specifically to keratinocytes. In contrast, HPV genomes can replicate in various undifferentiated cell lines regardless of their natural permissiveness to infection, as long as the viral replication proteins E1 and E2 are expressed.
Collapse
Affiliation(s)
- C Desaintes
- Département des Biotechnologies URA 1644 du CNRS, Institut Pasteur, Paris, France
| | | |
Collapse
|
26
|
Desaintes C, Hallez S, Detremmerie O, Burny A. Wild-type p53 down-regulates transcription from oncogenic human papillomavirus promoters through the epithelial specific enhancer. Oncogene 1995; 10:2155-61. [PMID: 7784059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
High-risk Human Papillomavirus (HPV) E6 and E7 immortalizing oncoproteins are expressed from a promoter tightly regulated by an epithelial specific enhancer. To determine if the p53 tumour suppressor protein can modulate the transcription of these genes, we performed co-transfection experiments with plasmids containing the HPV type 16 or 18 long control regions linked to the chloramphenicol acetyl transferase gene, along with p53 expression vectors. Wild-type, but not mutant, murine or human p53 expression vectors reduced the activity of reporter constructs when co-transfected into HeLa or C33 cell lines. Mutations within the HPV TATA boxes did not significantly alter the levels of p53 repression, suggesting a TATA-independent mechanism. Deletion analyses mapped the p53-responsive domain to the constitutive 230 base pair epithelial specific enhancer. In addition, the enhancer could confer p53-mediated repression when placed upstream of a heterologous promoter.
Collapse
Affiliation(s)
- C Desaintes
- Laboratoire de chimie biologique, Université Libre de Bruxelles, Rhode-St-Genèse, Belgium
| | | | | | | |
Collapse
|
27
|
Desaintes C, Hallez S, Van Alphen P, Burny A. Transcriptional activation of several heterologous promoters by the E6 protein of human papillomavirus type 16. J Virol 1992; 66:325-33. [PMID: 1309249 PMCID: PMC238291 DOI: 10.1128/jvi.66.1.325-333.1992] [Citation(s) in RCA: 61] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
The E6 protein of human papillomavirus type 16 (HPV-16), along with E7, is responsible for the HPV-induced malignant transformation of the cervix. However, the mechanism of this transformation activity is not well understood. We investigated whether the entire E6 protein of HPV-16 could act as an activator of transcription. Experiments in which NIH 3T3 cells were cotransfected with an E6 expression vector together with the reporter chloramphenicol acetyltransferase (CAT) gene linked to various minimal promoters indicated that E6 could activate transcription from a series of viral TATA-containing promoters. Mutations or deletions that affected all upstream regulatory elements present in the thymidine kinase (TK) promoter, such as the GC and CAAT boxes, reduced the level of E6-induced transcription. However, compared with the basal level, these truncated promoters were still activated by E6. Although site-directed mutations of the TATA sequence present in the TK or human immunodeficiency virus long terminal repeat promoters reduced the level of basal transcription, they did not abolish the E6-mediated activation. Moreover, E6 could restore almost completely the full level of wild-type E6-induced transcription as long as the upstream regulatory elements (GC/CAAT in the TK promoter, NF-kappa B in the human immunodeficiency virus long terminal repeat) were intact. This dual interaction of HPV-16 E6 is reminiscent of the activity of a coactivator.
Collapse
Affiliation(s)
- C Desaintes
- Laboratoire de Chimie Biologique, Faculté des Sciences, Université Libre de Bruxelles, Rhode-St-Genèse, Belgium
| | | | | | | |
Collapse
|